Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naproxen sodium/sumatriptan - Old API Wind-down

Drug Profile

Naproxen sodium/sumatriptan - Old API Wind-down

Alternative Names: MT-400; Naproxen sodium/sumatriptan succinate; SumaRT/Nap; Sumatriptan/naproxen sodium; Suvexx; Trexima; Treximet

Latest Information Update: 16 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline; POZEN
  • Developer Currax Pharmaceuticals; Nuvo Pharmaceuticals; Old API Wind-down Ltd
  • Class Anti-inflammatories; Antimigraines; Indoles; Naphthaleneacetic acids; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Sulfonamides; Tryptamines
  • Mechanism of Action Cyclooxygenase inhibitors; Serotonin 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Migraine

Most Recent Events

  • 14 May 2019 Nuvo Pharmaceuticals expects review decision for a New Drug Submission for Migraine by Health Canada in first half of 2020
  • 03 May 2019 Preregistration for Migraine in Canada (PO)
  • 30 Apr 2019 Currax Pharmaceuticals acquired all the assets of Pernix Therapeutics ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top